Koers Aurinia Pharmaceuticals Inc. Toronto S.E.
Aandelen
AUP
CA05156V1022
Biotechnologie & Medisch Onderzoek
Omzet 2024 * | 227 mln. 310 mln. 211 mln. | Omzet 2025 * | 282 mln. 385 mln. 262 mln. | Marktkapitalisatie | 780 mln. 1,06 mld. 724 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | 9 mln. 12,27 mln. 8,35 mln. | Nettowinst (verlies) 2025 * | 71 mln. 96,8 mln. 65,84 mln. | EV/omzet 2024 * | 1,7 x |
Nettoliquiditeiten 2024 * | 395 mln. 539 mln. 367 mln. | Nettoliquiditeiten 2025 * | 448 mln. 611 mln. 415 mln. | EV/omzet 2025 * | 1,18 x |
K/w-verhouding 2024 * |
94,3
x | K/w-verhouding 2025 * |
11,6
x | Werknemers | 300 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,93% |
Recentste transcriptie over Aurinia Pharmaceuticals Inc.
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Michael Martin
FOU | Founder | 52 | 16-06-93 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Robert Foster
FOU | Founder | 65 | 16-06-93 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Robert Foster
FOU | Founder | 65 | 16-06-93 |
R. MacKay-Dunn
BRD | Director/Board Member | 73 | 26-06-19 |
Peter Greenleaf
CEO | Chief Executive Officer | 54 | 29-04-19 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+15,58% | 122 mld. | |
+16,60% | 113 mld. | |
+17,55% | 26,22 mld. | |
-24,33% | 19,01 mld. | |
-19,14% | 15,71 mld. | |
-17,95% | 15,22 mld. | |
-46,81% | 14,72 mld. | |
+58,78% | 14,58 mld. | |
+4,91% | 13,84 mld. |